PBOC Scraps FX Risk Reserves to Curb Rapid Yuan Appreciation 
Australian Job Advertisements Hit 16-Month High as Labour Market Stays Resilient 
Dominican Republic Unveils Massive Rare Earth Deposits to Boost High-Tech and Energy Sectors 
Asian Stocks Tumble as US-Iran Conflict Escalates and Oil Prices Surge 
Nvidia to Launch New AI Inference Processor to Boost OpenAI Performance 
Australian Dollar Rallies on Hawkish RBA Outlook; Yen Slips as BOJ Faces Political Pressure 
Qantas Shares Plunge 10% as Iran Strikes Send Oil Prices Soaring and Disrupt Global Flights 
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates 
Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom 
The strikes on Iran show why quitting oil is more important than ever 
China’s New Home Prices Post Sharpest Drop Since 2022 Amid Ongoing Property Slump 
Strait of Hormuz LNG Crisis Triggers Global Energy Market Shock 
Nintendo Share Sale: MUFG and Bank of Kyoto to Sell Stakes in Strategic Unwinding 
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline 
OpenAI Secures $110 Billion Funding Round at $840 Billion Valuation Ahead of IPO 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
